STTT：抑制RNA结合蛋白，增强卵巢癌免疫治疗

Core Viewpoint - The study identifies RNA-binding proteins (RBPs) as key regulators of immune evasion in high-grade serous ovarian cancer (C5-HGSC), suggesting that inhibiting IGF2BP1 can enhance the efficacy of PD-1 blockade therapy [2][4][6]. Group 1: Research Findings - The research integrates single-cell RNA sequencing with bulk RNA sequencing data, marking the first discovery that RBPs are critical for immune evasion in C5-HGSC [4]. - IGF2BP1 is confirmed as a core mediator of immune evasion in both in vitro and in vivo models, functioning by accelerating the degradation of IRF1 protein to block gamma-interferon signaling and inhibit MHC-I antigen presentation [4]. - The study reveals that IGF2BP1 dissociates the relationship between PD-L1 expression and IRF1-dependent transcription, thereby limiting immune cell infiltration and T cell activation [4]. Group 2: Therapeutic Implications - The small molecule compound BTYNB effectively inhibits IGF2BP1 and can work synergistically with PD-1 blockade to reverse immune evasion in vivo [4]. - The findings are validated using multispectral imaging technology in human HGSC tissue samples, highlighting the role of cancer embryonic RBPs as molecular drivers of the C5-HGSC subtype [4][6].